MBX•benzinga•
MBX Biosciences Q4 2024 GAAP EPS $(0.47) Beats $(0.59) Estimate, $262.1M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2024; Expected To Support Operations Into Mid-2027
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 17, 2025 by benzinga